中国卵巢上皮性癌维持治疗指南(2021年)

2021-08-30 中国抗癌协会妇科肿瘤专业委员会 中国实用妇科与产科杂志

卵巢恶性肿瘤是女性生殖系统常见的恶性肿瘤之一, 中国人群卵巢癌新发病例为 52 100 例/年,死亡达 22 500 例/年。由于缺乏有效的早期筛查手段,患者就诊时多为晚期,中国卵巢癌患者 5年生存率

中文标题:

中国卵巢上皮性癌维持治疗指南(2021年)

发布日期:

2021-08-30

简要介绍:

卵巢恶性肿瘤是女性生殖系统常见的恶性肿瘤之一, 中国人群卵巢癌新发病例为 52 100 /年,死亡达 22 500 /。由于缺乏有效的早期筛查手段,患者就诊时多为晚期,中国卵巢癌患者 5年生存率约为 40%。近年来,随着抗血管生成药物、聚腺苷二磷酸核糖聚合酶(poly ADPribose polymerasePARP)抑制剂等靶向治疗药物的出现及相关维持治疗研究结果的公布,有效地延长了晚期患者的生存期,改变了卵巢癌的治疗策略。为指导和规范卵巢上皮性癌的维持治疗,中国抗癌协会妇科肿瘤专业委员会(CGCS)于20203月发布了《中国卵巢上皮性癌维持治疗专家共识(2020)》。

相关资料下载:
[AttachmentFileName(sort=1, fileName=_中国卵巢上皮性癌维持治疗指南(2021年版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=d6fb71c00216e831, title=中国卵巢上皮性癌维持治疗指南(2021年), enTitle=, guiderFrom=中国实用妇科与产科杂志, authorId=0, author=, summary=卵巢恶性肿瘤是女性生殖系统常见的恶性肿瘤之一, 中国人群卵巢癌新发病例为 52 100 例/年,死亡达 22 500 例/年。由于缺乏有效的早期筛查手段,患者就诊时多为晚期,中国卵巢癌患者 5年生存率, cover=https://img.medsci.cn/2021830/1630288212186_92910.png, journalId=0, articlesId=null, associationId=1526, associationName=中国抗癌协会妇科肿瘤专业委员会, associationIntro=, copyright=0, guiderPublishedTime=Mon Aug 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #231f20;">卵巢恶性肿瘤是女性生殖系统常见的恶性肿瘤之一, </span><span style="color: #231f20;">中国人群卵巢癌新发病例为 </span><span style="color: #231f20;">52 100 </span><span style="color: #231f20;">例</span><span style="color: #231f20;">/</span><span style="color: #231f20;">年,死亡达 </span><span style="color: #231f20;">22 500 </span><span style="color: #231f20;">例</span><span style="color: #231f20;">/</span><span style="color: #231f20;">年</span><span style="color: #231f20;">。由于缺乏有效的早期筛查手段,患者就诊时多为</span><span style="color: #231f20;">晚期,中国卵巢癌患者 </span><span style="color: #231f20;">5</span><span style="color: #231f20;">年生存率约为 </span><span style="color: #231f20;">40%</span><span style="color: #231f20;">。近年来,随</span><span style="color: #231f20;">着抗血管生成药物、聚腺苷二磷酸核糖聚合酶(</span><span style="color: #231f20;">poly ADP</span><span style="color: #231f20;">ribose polymerase</span><span style="color: #231f20;">,</span><span style="color: #231f20;">PARP</span><span style="color: #231f20;">)抑制剂等靶向治疗药物的出现及</span><span style="color: #231f20;">相关维持治疗研究结果的公布,有效地延长了晚期患者的</span><span style="color: #231f20;">生存期,改变了卵巢癌的治疗策略。</span><span style="color: #231f20;">为指导和规范卵巢上皮性癌的维持治疗,中国抗癌协</span><span style="color: #231f20;">会妇科肿瘤专业委员会(</span><span style="color: #231f20;">CGCS</span><span style="color: #231f20;">)于</span><span style="color: #231f20;">2020</span><span style="color: #231f20;">年</span><span style="color: #231f20;">3</span><span style="color: #231f20;">月发布了</span><span style="color: #231f20;">《中国</span><span style="color: #231f20;">卵巢上皮性癌维持治疗专家共识(</span><span style="color: #231f20;">2020</span><span style="color: #231f20;">)》。</span></p>, tagList=[TagDto(tagId=90750, tagName=卵巢上皮性癌), TagDto(tagId=114220, tagName=聚腺苷二磷酸核糖聚合酶抑制剂)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=90750, guiderKeyword=卵巢上皮性癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=29842, appHits=503, showAppHits=0, pcHits=1013, showPcHits=29313, likes=2, shares=24, comments=13, approvalStatus=1, publishedTime=Mon Aug 30 09:50:43 CST 2021, publishedTimeString=2021-08-30, pcVisible=1, appVisible=1, editorId=92910, editor=rayms, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=6, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Aug 30 00:07:03 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 22:14:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=_中国卵巢上皮性癌维持治疗指南(2021年版).pdf)])
_中国卵巢上皮性癌维持治疗指南(2021年版).pdf
下载请点击:
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1193634, encodeId=9f73119363441, content=😁, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21075636568, createdName=ms1000001810071692, createdTime=Tue Feb 15 15:45:10 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078836, encodeId=48a210e883628, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>NICE,太赞了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f12852832, createdName=1209273456, createdTime=Fri Dec 10 18:13:26 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074330, encodeId=a16910e433024, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7995632374, createdName=Arwen_Lau, createdTime=Fri Nov 26 21:11:38 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070541, encodeId=619d10e0541e7, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db665713833, createdName=ms6000000788824496, createdTime=Mon Nov 15 21:22:03 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070077, encodeId=a3fd10e00775a, content=谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211113/7895119968f344f1b1854ae8a9ce7fad/c9580634e9e4450899057268c69ec436.jpg, createdBy=861b1485468, createdName=陌上咖啡, createdTime=Sun Nov 14 09:51:47 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2022-02-15 ms1000001810071692

    😁

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1193634, encodeId=9f73119363441, content=😁, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21075636568, createdName=ms1000001810071692, createdTime=Tue Feb 15 15:45:10 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078836, encodeId=48a210e883628, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>NICE,太赞了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f12852832, createdName=1209273456, createdTime=Fri Dec 10 18:13:26 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074330, encodeId=a16910e433024, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7995632374, createdName=Arwen_Lau, createdTime=Fri Nov 26 21:11:38 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070541, encodeId=619d10e0541e7, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db665713833, createdName=ms6000000788824496, createdTime=Mon Nov 15 21:22:03 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070077, encodeId=a3fd10e00775a, content=谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211113/7895119968f344f1b1854ae8a9ce7fad/c9580634e9e4450899057268c69ec436.jpg, createdBy=861b1485468, createdName=陌上咖啡, createdTime=Sun Nov 14 09:51:47 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2021-12-10 1209273456

    #学习#NICE,太赞了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1193634, encodeId=9f73119363441, content=😁, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21075636568, createdName=ms1000001810071692, createdTime=Tue Feb 15 15:45:10 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078836, encodeId=48a210e883628, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>NICE,太赞了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f12852832, createdName=1209273456, createdTime=Fri Dec 10 18:13:26 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074330, encodeId=a16910e433024, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7995632374, createdName=Arwen_Lau, createdTime=Fri Nov 26 21:11:38 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070541, encodeId=619d10e0541e7, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db665713833, createdName=ms6000000788824496, createdTime=Mon Nov 15 21:22:03 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070077, encodeId=a3fd10e00775a, content=谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211113/7895119968f344f1b1854ae8a9ce7fad/c9580634e9e4450899057268c69ec436.jpg, createdBy=861b1485468, createdName=陌上咖啡, createdTime=Sun Nov 14 09:51:47 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2021-11-26 Arwen_Lau

    学习了,谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1193634, encodeId=9f73119363441, content=😁, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21075636568, createdName=ms1000001810071692, createdTime=Tue Feb 15 15:45:10 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078836, encodeId=48a210e883628, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>NICE,太赞了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f12852832, createdName=1209273456, createdTime=Fri Dec 10 18:13:26 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074330, encodeId=a16910e433024, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7995632374, createdName=Arwen_Lau, createdTime=Fri Nov 26 21:11:38 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070541, encodeId=619d10e0541e7, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db665713833, createdName=ms6000000788824496, createdTime=Mon Nov 15 21:22:03 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070077, encodeId=a3fd10e00775a, content=谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211113/7895119968f344f1b1854ae8a9ce7fad/c9580634e9e4450899057268c69ec436.jpg, createdBy=861b1485468, createdName=陌上咖啡, createdTime=Sun Nov 14 09:51:47 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2021-11-15 ms6000000788824496

    👍

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1193634, encodeId=9f73119363441, content=😁, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21075636568, createdName=ms1000001810071692, createdTime=Tue Feb 15 15:45:10 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078836, encodeId=48a210e883628, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>NICE,太赞了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9f12852832, createdName=1209273456, createdTime=Fri Dec 10 18:13:26 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074330, encodeId=a16910e433024, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7995632374, createdName=Arwen_Lau, createdTime=Fri Nov 26 21:11:38 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070541, encodeId=619d10e0541e7, content=👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db665713833, createdName=ms6000000788824496, createdTime=Mon Nov 15 21:22:03 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070077, encodeId=a3fd10e00775a, content=谢谢分享!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211113/7895119968f344f1b1854ae8a9ce7fad/c9580634e9e4450899057268c69ec436.jpg, createdBy=861b1485468, createdName=陌上咖啡, createdTime=Sun Nov 14 09:51:47 CST 2021, time=2021-11-14, status=1, ipAttribution=)]
    2021-11-14 陌上咖啡

    谢谢分享!

    0

拓展阅读

中国卵巢上皮性癌维持治疗专家共识(2019)

中国抗癌协会妇科肿瘤专业委员会 · 2019-06-05

中国卵巢上皮性癌维持治疗专家共识(2020)

中国抗癌协会妇科肿瘤专业委员会 · 2020-03-10

中国卵巢上皮性癌维持治疗指南(2022年版)

中国抗癌协会妇科肿瘤专业委员会 · 2022-01-02

卵巢上皮性癌一线化疗中国专家共识

中国抗癌协会妇科肿瘤专业委员会 · 2022-08-15